Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab

Alector Inc. (NASDAQ:ALEC) is one of the best stocks under $3 to invest in. On October 21, Alector announced the topline results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab (AL001) in individuals with frontotemporal dementia due to a progranulin gene mutation (FTD-GRN).

The 96-week, double-blind INFRONT-3 trial, developed in collaboration with GSK, did not meet the clinical co-primary endpoint of slowing FTD-GRN progression, as measured by the Clinical Dementia Rating plus National Alzheimer’s Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes (CDR plus NACC FTLD-SB).

Alector Announces Topline Results from Phase 3 INFRONT-3 Clinical Trial Evaluating Latozinemab

In collaboration with GSK, nivisnebart (AL101/GSK4527226) is being evaluated in the PROGRESS-AD, a global, 76-week Phase 2 clinical trial for individuals with early Alzheimer’s disease/AD. Enrollment was completed in April 2025, with trial completion expected in 2026 and an independent interim analysis planned for H1 2026.

Alector Inc. is a late-stage clinical biotechnology company that develops therapies to counter the devastating progression of neurodegenerative diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.